BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced an oral presentation and two poster presentations on its preclinical immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22, 2026, in San Diego, California.

Oral Presentation Details

Title: TFF2 deficiency amplifies IL-1B-driven inflammation and promotes aging-associated gastric tumor progressionAbstract #: 6822Date and Time: April 21, 2026, 2:30-4:30 p.m. PT (5:30-7:30 p.m. ET)Session Category: Tumor BiologySession Title: Aging Micro- and Macro-Environments in Tumor Progression and TherapyPresenters: Shuang Li, MD, PhD, and Timothy C. Wang, MD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (Tonix co-authors: Seth Lederman, MD, Chief Executive Officer, and Bruce L. Daugherty, PhD, MBA, Executive Vice President of Research)

Poster Presentation Details

Title: In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodiesPoster #: 6550Date and Time: April 21, 2026, 2:00-5:00 p.m. PT (5:00-8:00 p.m. ET)Session Category: Clinical ResearchSession Title: Immune Checkpoint BlockadeLocation: Poster Section 44, Board 16Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

Title: Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic micePoster #: 7940Date and Time: April 22, 2026, 9:00 a.m.-12:00 p.m. PT (12:00-3:00 p.m. ET)Session Category: Clinical ResearchSession Title: Tumor Microenvironment Modulators Location: Poster Section 49, Board 15Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

Copies of the Company's presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com.

About TNX-1700TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia University, is in the pre-Investigational New Drug (IND) stages of development.

Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(R) (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) Symtouch(R) (sumatriptan injection 3 mg) and Tosymra(R) (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor ContactsJessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 799-8599

Brian Korbastr partners(917) 653-5122brian.korb@astrpartners.com

Media ContactsDeborah ElsonTonix Pharmaceuticals deborah.elson@tonixpharma.com

Ray JordanPutnam Insightsray@putnaminsights.com

COMTEX_475443688/2010/2026-03-17T16:35:00

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced an oral presentation and two poster presentations on its preclinical immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22, 2026, in San Diego, California.

Oral Presentation Details

Title: TFF2 deficiency amplifies IL-1B-driven inflammation and promotes aging-associated gastric tumor progressionAbstract #: 6822Date and Time: April 21, 2026, 2:30-4:30 p.m. PT (5:30-7:30 p.m. ET)Session Category: Tumor BiologySession Title: Aging Micro- and Macro-Environments in Tumor Progression and TherapyPresenters: Shuang Li, MD, PhD, and Timothy C. Wang, MD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (Tonix co-authors: Seth Lederman, MD, Chief Executive Officer, and Bruce L. Daugherty, PhD, MBA, Executive Vice President of Research)

Poster Presentation Details

Title: In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodiesPoster #: 6550Date and Time: April 21, 2026, 2:00-5:00 p.m. PT (5:00-8:00 p.m. ET)Session Category: Clinical ResearchSession Title: Immune Checkpoint BlockadeLocation: Poster Section 44, Board 16Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

Title: Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic micePoster #: 7940Date and Time: April 22, 2026, 9:00 a.m.-12:00 p.m. PT (12:00-3:00 p.m. ET)Session Category: Clinical ResearchSession Title: Tumor Microenvironment Modulators Location: Poster Section 49, Board 15Presenter: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

Copies of the Company's presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com.

About TNX-1700TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia University, is in the pre-Investigational New Drug (IND) stages of development.

Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(R) (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) Symtouch(R) (sumatriptan injection 3 mg) and Tosymra(R) (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor ContactsJessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 799-8599

Brian Korbastr partners(917) 653-5122brian.korb@astrpartners.com

Media ContactsDeborah ElsonTonix Pharmaceuticals deborah.elson@tonixpharma.com

Ray JordanPutnam Insightsray@putnaminsights.com

COMTEX_475443688/2010/2026-03-17T16:35:00